🔗 Share this article

Given that the United States undertakes unprecedented adjustments to its vaccine guidelines, a particular individual has emerged in a surprising turn: Høeg, a Danish American sports physician and public health researcher who initially gained attention by questioning coronavirus shots in the global health crisis and has focused upon possible deaths following Covid immunization in her short position at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Immunization Program

Public health authorities planned to announce sweeping revisions to the childhood vaccine schedule in December, aligning the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US out of alignment with much of the global community with little proof for public health gain. The planned update has been delayed until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to speak at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this year.

Consolidating Power at the Regulatory Body

This interim role could signify a closer partnership between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it signals a increased emphasis upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for halting certain pediatric immunization guidelines in the US so as to align more like the Danish model, a nation with comprehensive healthcare and a population about the population of Wisconsin’s.

To date public appearances, she has kept her attention on vaccination policy – usually the purview of Dr. Prasad, chief of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Expertise

Dr. Høeg has no obvious background in pharmaceutical research, approval processes or management, which has been customary for former directors of the biologics center. She has worked at the FDA as a senior adviser to the commissioner and CBER since March.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in running a major agency. She lacks background in drug approvals.”

Former commissioners of the center would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, commented Janet Woodcock. “Objectively, she doesn’t have the type of experience that former directors who headed the center have had.”

This division has an enormous workload at the FDA, the former commissioner emphasized.

“The public just zeroes in on the innovative therapies, but the generic drug division approves thousands of generic drugs. There’s a biosimilars program, non-prescription drug unit and so forth, and every single one have to be managed,” Dr. Woodcock said. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major leadership aspect to the job, which supervises over 5,000 personnel. “It is a massive administrative position, if you do it right,” she said.

Response and Controversial Programs

In response to questions about Dr. Høeg's credentials and whether this selection signifies more teamwork among agency officials on immunizations, a spokesperson stated that the “concerns are based on inaccurate assumptions”.

“This background aligns with the responsibilities of her position,” the official stated, pointing to the months Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg takes over the agency head's new expedited review system, a controversial rapid drug-approval program that apparently concerned her predecessors. “By what process are these medications being picked for this expedited pathway? Who makes the decisions?” Dr. Howard said. “There is a lot of secrecy going on at the FDA right now.”

Broadly speaking, he said, “the FDA looks to be trending towards laxer regulations of all drugs, with the exception of immunizations.”

Established Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if problematic, history, some experts said. She published a research paper using unverified volunteer-provided data to assess the incidence of myocarditis after Covid vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccines are more dangerous than they are.

Among her “policy goals” for the incoming federal leadership included changing regulations for recently developed shots and discontinuing “unnecessary” vaccines, she remarked after the election on a audio program. At the agency, Høeg has according to sources proposed preventing young men from getting COVID-19 vaccinations.

“She is an thorough true believer who begins with her preconceived notions and tailors the evidence to retrofit the evidence in a extremely misleading, dishonest manner,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Høeg joined other dissenters, {like|